OHR Pharmaceutical Inc.

Financials

v3.7.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2017
Sep. 30, 2016
CURRENT ASSETS    
Cash and cash equivalents $ 9,521,236 $ 12,546,890
Prepaid expenses and other current assets 570,214 738,118
Total Current Assets 10,091,450 13,285,008
EQUIPMENT, net 172,404 198,631
OTHER ASSETS    
Security deposit 12,243 12,243
Intangible assets, net 14,648,969 15,208,219
Goodwill 740,912 740,912
TOTAL ASSETS 25,665,978 29,445,013
CURRENT LIABILITIES    
Accounts payable and accrued expenses 6,780,781 4,394,068
Notes payable 261,326 87,798
Total Current Liabilities 7,042,107 4,481,866
TOTAL LIABILITIES 7,042,107 4,481,866
STOCKHOLDERS' EQUITY    
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively  
Common stock; 180,000,000 shares authorized, $0.0001 par value, 35,961,396 and 32,076,396 shares issued and outstanding, respectively 3,596 3,207
Additional paid-in capital 117,563,612 109,237,551
Accumulated deficit (98,943,337) (84,277,611)
Total Stockholders' Equity 18,623,871 24,963,147
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 25,665,978 $ 29,445,013
v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
OPERATING EXPENSES        
General and administrative $ 1,404,060 $ 2,966,363 $ 3,150,416 $ 4,184,492
Research and development 5,993,928 4,043,859 10,925,072 6,120,139
Depreciation and amortization 291,876 296,077 590,311 593,816
Gain on settlement of accounts payable   (710,264)   (710,264)
OPERATING LOSS 7,689,864 6,596,035 14,665,799 10,188,183
OTHER INCOME (EXPENSE)        
Change in fair value of contingent consideration   1,305,623   (1,251,926)
Other income       3,419
Interest income (expense), net (208) 5,553 73 6,369
Total Other Income (Expense) (208) 1,311,176 73 (1,242,138)
LOSS FROM OPERATIONS BEFORE INCOME TAXES (7,690,072) (5,284,859) (14,665,726) (11,430,321)
NET LOSS $ (7,690,072) $ (5,284,859) $ (14,665,726) $ (11,430,321)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (0.21) $ (0.17) $ (0.43) $ (0.37)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:        
BASIC AND DILUTED (in shares) 36,738,396 31,344,424 34,381,781 30,906,114
v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Mar. 31, 2017
Mar. 31, 2016
OPERATING ACTIVITIES    
Net loss $ (14,665,726) $ (11,430,321)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services 633,697 715,952
Stock option expense 846,270 1,724,375
Change in fair value of contingent consideration   1,251,926
Depreciation 31,060 31,494
Amortization of intangible assets 559,250 562,322
Gain on settlement of accounts payable   (710,264)
Changes in operating assets and liabilities    
Prepaid expenses and deposits 310,429 98,009
Accounts payable and accrued expenses 2,386,713 987,180
Net Cash Used in Operating Activities (9,898,307) (6,769,327)
INVESTING ACTIVITIES    
Purchase of property and equipment (4,833) (12,103)
Net Cash Used in Investing Activities (4,833) (12,103)
FINANCING ACTIVITIES    
Proceeds for issuance of common stock for cash 6,846,483  
Proceeds from warrants exercised for cash 118,801 13,540
Repayments of short-term notes payable (87,798) (48,063)
Net Cash Provided by/(Used in) Financing Activities 6,877,486 (34,523)
NET CHANGE IN CASH AND CASH EQUIVALENTS (3,025,654) (6,815,953)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 12,546,890 28,697,323
CASH AND CASH EQUIVALENTS AT END OF PERIOD 9,521,236 21,881,370
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION    
Interest 798  
NON CASH FINANCING ACTIVITIES:    
Settlement of contingent consideration   2,061,136
Financing of insurance premiums through issuance of short term notes $ 261,326 $ 215,810